Amprologix to develop new antibiotics with Ingenza
RNS Reach
AIM: FIPP
20 September 2018
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - Amprologix to develop new antibiotics to help combat antimicrobial resistance in partnership with Ingenza
Frontier IP, a specialist in commercialising university intellectual property, today announces it has taken a 10 per cent stake in Amprologix Limited ("the Company"), a spin-out from the University of Plymouth.
The company has been established to introduce new antibiotics, helping to tackle antimicrobial resistance, a major threat to human health globally. It will develop and commercialise the work of Dr Mathew Upton, Professor in Medical Microbiology at the University's School of Biomedical Sciences.
The first product from the Company is expected to be a cream containing epidermicin, one of the new antibiotics being developed to combat infections caused by antibiotic-resistant bacteria. Epidermicin can rapidly kill harmful bacteria including MRSA (methicillin resistant Staphylococcus aureus), Streptococcus and Enterococcus at very low doses, even if they are resistant to other antibiotics.
No new classes of antibiotics have been introduced into clinical use for the past 30 years, and the company is aiming to meet a growing need for new antibiotics as harmful microbes become increasingly drug resistant.
It has already secured industry involvement through a partnership with world-leading biotechnology and synthetic biology company Ingenza.
The new company is focused on four areas:
· Developing epidermicin for commercial use
· Discovering additional sources for new classes of antibiotics
· Using Artificial Intelligence to improve antibiotic properties, working with Ingenza, IBM and the National Physical Laboratory
· Developing efficient techniques to manufacture antibiotics at scale in partnership with Ingenza
In a relevant infection model, a single dose of epidermicin was as effective as six doses of the current standard of care. The antibiotic was initially recovered from a skin bacterium named Staphylococcus epidermidis, but can now be produced in a microbe suitable for industrial scale-up, using synthetic biology methods developed by Ingenza.
Professor Upton initially developed the patented technology working closely with UMI3 Ltd at The University of Manchester, which now takes a 13 per cent stake in the new business.
The World Health Organisation warned in February this year that "antibiotic resistance is one of the biggest threats to global health, food security, and development today".
A UK government review in 2015, chaired by economist Jim O'Neill, estimated that by 2050, the global cost of antibiotic resistance will rise to US$100 trillion and drug resistant infections will cause 10 million deaths a year, eclipsing the current toll from cancer and diabetes combined. The government estimates there are currently 5,000 deaths each year in the UK because antibiotics no longer work for some infections. https://www.gov.uk/government/news/30-million-of-funding-to-tackle-antimicrobial-resistance
Neil Crabb, chief executive of Frontier IP, said: "We are delighted to work with Amprologix to commercialise these potentially life-saving antibiotics, and with a leading industrial partner in the area. It is further sign our business model is gaining traction with universities and industry alike."
Professor Mathew Upton, chief scientific officer of Amprologix, said: "It is very exciting to form a new company to take forwards our portfolio of novel antimicrobial compounds. Epidermicin, our lead candidate antibiotic, has excellent potential for treating and preventing serious, drug resistant infections. With our current team, the company will be the ideal vehicle to take epidermicin to the clinic."
Dr Ian Fotheringham, managing director of Ingenza, said: "This unique partnership fully exploits the synergy of Ingenza's versatile bio-manufacturing technologies and Amprologix's lead in discovering exciting new antimicrobial classes, spearheaded by Dr Upton's innovative research."
ENQUIRIES
|
Frontier IP Group Plc |
T: 0131 240 1251 |
|
Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations andrew.johnson@frontierip.co.uk Company website: www.frontierip.co.uk |
M: 07464 546 025 |
|
Cenkos Securities plc (Nominated Adviser and Joint Broker) |
T: 0131 220 6939 |
|
Neil McDonald / Beth McKiernan |
|
|
Peterhouse Corporate Finance Limited (Joint Broker) |
T: 020 7469 0935 |
|
Lucy Williams |
|
|
Kreab (Financial PR) |
T: 020 7074 1800 |
|
Robert Speed / Matthew Jervois NOTES TO EDITORS Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development. Frontier IP and the University of Plymouth: Frontier IP has forged a strong relationship with the University of Plymouth to commercialise intellectual property. Other collaborations include: · Fieldwork Robotics: developing advanced soft robotics for harvesting fruit and vegetables. The technology has attracted strong industry interest. · The Vaccine Group: work includes creating novel vaccines to prevent viruses from jumping the species barrier from animals to humans · Pulsiv Solar: US and European patents granted on its novel technology to improve the energy efficiency of photovoltaic cells and power conversion · Molendotech: the company has developed a novel test to detect faecal bacteria in water, which is now being commercialised by Palintest, a subsidiary of FTSE 100 life protection and hazard detection group Halma · PoreXpert: the company has developed sophisticated software to model in three dimensions the porosity of materials
|
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 7 hours ago Johnson Matthey
- 9 hours ago Galliford Try
- 9 hours ago Galliford Try
- 9 hours ago Centrica
- 10 hours ago Smith & Nephew